Press Releases | News

Press Releases

April 18, 2013
Saladax Recruits Top Talent as Commercial Introduction of MyCare™ Portfolio of Oncology Diagnostics Nears — (Read More)
March 5, 2013
Saladax Biomedical Series-D Financing Finalized — (Read More)
February 15, 2013
Saladax Enters Into Distribution Agreement with Transmedic for MyCare™ Portfolio of Oncology Therapeutic Dose Management Assays — (Read More)
February 11, 2013
Saladax Biomedical Laboratories to Offer the Full Portfolio of MyCare™ Therapeutic Dose Management Assays in the United States — (Read More)
December 6, 2012
Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory As Part of the Company’s Commercialization Strategy — (Read More)
November 16, 2012
Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer — (Read More)
September 12, 2012
Saladax Biomedical, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York City — (Read More)
September 6, 2012
Saladax Biomedical, Inc. Expands Distribution of MyCare™ Products in Israel — (Read More)
August 6, 2012
Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb — (Read More)
July 9, 2012
Saladax Biomedical, Inc. Extends Availability of its MyCare Portfolio in Europe — (Read More)
June 15, 2012
Saladax Biomedical, Inc. Appoints Kevin M. Harter as President and Chief Executive Officer — (Read More)
April 23, 2012
Saladax Biomedical, Inc. Expands Distribution of My5-FU in Egypt and Throughout the Middle East North African (MENA) Region — (Read More)
March 12, 2012
Saladax Biomedical, Inc. Expands Distribution of My5-FU in Spain and Portugal — (Read More)
February 13, 2012
CESAR and Saladax Biomedical Collaborate on a Study of Optimized 5-FU Dosing in Colorectal Cancer Patients — (Read More)
January 27, 2012
Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer — (Read More)
January 10, 2012
Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space — (Read More)
January 4, 2012
Saladax Biomedical, Inc. to Present at Biotech Showcase 2012 — (Read More)
Press Releases | News

News

August 6, 2012
Fierce Medical Devices – Saladax inks companion Dx deal with Bristol-Myers — (Read More)
June 15, 2012
Dow Jones VentureWire – Saladax Biomedical Names CEO Ahead of Series D, Diagnostic Test Launches — (Read More)
MedCity News – New CEO leads expansion of personalized medicine dosing assay company — (Read More)
January 27, 2012
ChinaBio Today – For Saladax Biomedical, China Could Be the Largest Market — (Read More)
January 24, 2012
Drug Discovery & Development – Therapy Dose Management During Clinical Development of Oncology Products — (Read More)
November 11, 2011
Medical Device Daily – Saladax’s MyCare assays allow for stronger dose optimization — (Read More)
October 21, 2011
Saladax: Providing Biomedical Opportunities in Pennsylvania — (Read More)
MergerMarket – Saladax, a Bethlehem, Pennsylvania-based cancer diagnostic company, could exit in 24 to 36 months after it builds additional value — (Read More)
September 23, 2011
Clinica – J&J Dx unit joins BMS/Saladax Alzheimer’s collaboration — (Read More)
September 1, 2011
The FDA and Laboratory – The Brouhaha Continues — (Read More)
March 4, 2011
IVD Technology – Innovation helping to personalize medicine — (Read More)
October 1, 2010
CAP Today – Uneasy Alliance — TDM, Oncology Drugs Saladax CEO Salvatore Salamone featured in College of American Pathologists — (Read More)
July 1, 2010
HemOnc today – Maximum tolerated exposure: A more rational approach to drug dosing — (Read More)
September 1, 2009
Saladax cited by U.S. Commerce Dept. Secretary Locke during Ben Franklin Technology Partners visit — (Read More)
May 1, 2009
Personalized Medicine Coalition Publishes The Case for Personalized Medicine, an Updated Report and Analysis on Advances and Challenges — (Read More)
April 1, 2009
Myriad Genetics Launches OnDose, Its Seventh Molecular Diagnostic Product OnDose Assists Oncologists in Maximizing Chemotherapy Efficacy and Reducing Toxicity — (Read More)
October 7, 2008
Myriad Genetics (Nasdaq: MYGN, www.myriad.com) Acquires Novel Therapeutic Drug Management Technology from Saladax Biomedical — (Read More)